Fertility tech refers to technology driven solutions used by men and women to monitor or preserve fertility. Fertility monitoring helps couples increase their chance of conceiving. Fertility preservation reduces the impact of one’s biological clock when making decisions on conceiving and family planning. The fertility tech ecosystem also includes players who support the fertility tech industry by offering patients assistance in navigating their fertility care decision-making and financing. These tech tools are gaining traction supported by several demographic, social, and economic factors such as delaying parenthood, decreasing male fertility, and a shortage of fertility clinics.
Fertility preservation services such as egg and sperm freezing face elevated near-term demand due to an increase in uncertainty caused by the pandemic.
Fertility test kits for men and women face supply chain challenges and potentially reduced demand as family formation and expansion tends to decline during periods of economic uncertainty.
Fertility tracking and monitoring apps expected to remain largely unaffected by the pandemic.
Natural Cycles and Ava have added features to monitor Covid-19 symptoms among their users.
The fertility tech market primarily includes products engaged in fertility monitoring and tracking, which includes at-home fertility/hormone measuring kits, fertility and ovulation monitoring and tracking app, and the men’s fertility test and sperm storage segments as well as fertility preservation services. Notably, among the disruptors and watchlist companies, egg freezing services had the smallest number of companies.
Most firms in the industry are pure-play companies, with the exception of leading disruptors EverlyWell, Kindbody, and Prelude Fertility. Around half of the disruptors and watchlist companies identified in this report are early stage, with the remainder split between seed and growth stages.
Integrated players EverlyWell and Prelude Fertility remain highest funded, followed by financial assistance players
While most disruptors cater to a single segment in the fertility tech ecosystem, one of the highest funded disruptors, Prelude Fertility, distinguishes itself by offering a range of services. Prelude’s offering includes sperm and egg freezing, embryo creation and transfer, and genetic screening for inherited diseases and abnormalities. The highest funded disruptor in this space as of August 2021 was fertility test kit provider, EverlyWell.
Most disruptors compete with their segmental peers with similar products, with the exception of at-home fertility/hormone measuring kits for women, where different bodily components are used to measure hormones. For instance, Natural Cycles uses temperature to measure ovulation, whereas Kegg measures cervical fluids to track hormone levels. Furthermore, WOOM is an exception to most period and fertility monitoring apps, as it looks to track and give more information on bodily functions, while other apps typically look to predict future cycles using the data.
Headquartered in Dublin and New York, LetsGetChecked (LGC) offers more than 100 at-home healthcare test kits for fertility, cholesterol, diabetes, thyroid, and Covid-19, among others. It provides the test results online and offers follow-up care through its telehealth and pharmacy offerings. As of June 2021, the company claimed to serve over 300 corporate customers, with over 2 million tests administered across the US and EU since its inception in 2015.
In the fertility tech space, the company offers two types of finger-prick test kits (a progesterone test and an ovarian reserve test) that allow samples to be gathered at home, later being mailed to the lab for analysis. The progesterone test assesses whether ovulation has occurred, and the ovarian reserve test measures the Anti-Mullerian Hormone (AMH) to indicate the number of a woman’s remaining eggs. LGC benefited from the Covid-19 pandemic promoting at-home healthcare and claims its revenue grew 1,500% YoY owing to the pandemic.
In June 2021, the company raised USD 150 million in Series D funding led by Casdin Capital, reaching unicorn status with a valuation of over USD 1 billion. The funds will be used to expand internationally and strengthen its telehealth services, pharmacy capabilities, and at-home testing.
Women's at-home fertility/hormone measuring kit:
Period and fertility monitoring and tracking app:
Egg freezing services and storage :
Incumbents in the fertility tech market include fertility clinics, medical device manufacturers, and testing kit providers. These companies generally opt to produce their own in-house innovations for the fertility tech market, as an extension of their current products and services. For instance, EarlySense offers a range of healthcare monitoring devices and also produces a device to monitor hormones and fertility for women.
DNA Diagnostics Center, a DNA diagnostics and testing provider, acquired Sperm Check in May 2018 to expand their testing to the fertility industry.
In addition to the healthcare enterprises, Google also has interests within the fertility tech industry, through subsidiary Fitbit’s wearables, which offers fertility tracking products, and has invested in a disruptor KindBody, an egg freezing service provider.
Google’s subsidiary Fitbit (acquired in November 2019) launched a period and fertility tracking feature to its wearables in early 2018, which has been available to all Fitbit app users since Q2 2018. Similar to the disruptor offerings, the platform allows women to enter data from each menstrual cycle, which is then used to predict future cycles and fertility periods.
In addition to the in-house offering through Fitbit, Google has also invested in Kindbody. Alphabet’s GV participated in Kindbody’s Series B funding in July 2020, and led its Series A funding in December 2019. Moreover, Spanish startup WOOM (offers a fertility tracking app) began at Google for Startups (Madrid) with the assistance from accelerator programs including Google Campus Residency.
No investor data is available